Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature-Reference-Cited by-同舟云学术

Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature

Published:2020-10-19 Issue:3 Volume:49 Page:549-553
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Meschiari Marianna^ORCID,Franconi Iacopo,Bacca Erica,Bianco Vincenzo,Orlando Gabriella,Cuomo Gianluca,Bedini Andrea,Mussini Cristina

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s15010-020-01539-9.pdf

Reference17 articles.

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.

2. Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017;65:158–61.

3. Rodríguez-Núñez O, Ripa M, Morata L, de la Calle C, Cardozo C, Fehér C, Pellicé M, Valcárcel A, Puerta-Alcalde P, Marco F, García-Vidal C, del Río A, Soriano A. J Martínez-Martínez Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136–9.

4. Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53:408–15.

5. Dietl B, Sánchez I, Arcenillas P, Cuchi E, Gómez L, González de Molina FJ, Boix-Palop L, Nicolás J, Calbo E. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes. Int J Antimicrobial Agents. 2018;51:498–5027.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Confronting multidrug-resistantKlebsiellameningitis after mid-clival Cerebrospinal Fluid leak repair: a therapeutic odyssey;BMJ Case Reports;2024-06

2. New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections;Antibiotics;2024-01-07

3. Case series; Ceftazidime/avibactam for treating post-neurosurgical ventriculitis and meningitis due to Carbapenem-resistant Klebsiella pneumonia (CRKP);Interdisciplinary Neurosurgery;2023-12

4. Tigecycline–Rifampicin Restrains Resistance Development in Carbapenem-Resistant Klebsiella pneumoniae;ACS Infectious Diseases;2023-09-05

5. Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature;Antibiotics;2023-08-17